<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03037073</url>
  </required_header>
  <id_info>
    <org_study_id>Duloxetine POM</org_study_id>
    <nct_id>NCT03037073</nct_id>
  </id_info>
  <brief_title>Duloxetine for Succinylcholine-induced Postoperative Myalgia</brief_title>
  <official_title>Impact of Duloxetine on Succinylcholine-induced Postoperative Myalgia During Direct Microlaryngoscopic Surgeries: Randomized Controlled Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For &gt;60 years, succinylcholine is still being administered as a selective relaxant for rapid&#xD;
      sequence intubation by anesthesiologists in many countries. It has been shown to possess&#xD;
      unique features such as low cost, fast-acting, short half-life, safe metabolites, and causing&#xD;
      excellent muscle relaxation for intubation. It has many side effects as well. Postoperative&#xD;
      myalgia (POM), with an incidence rate of ~41%-92%, is one of the most common side effects of&#xD;
      this drug and can take several days to cause significant discomfort in patients. However, its&#xD;
      effect is felt more in the throat, neck, shoulder, and abdominal muscles and is common among&#xD;
      patients with outpatient surgery. Due to its unknown real context of pathogenesis and in an&#xD;
      effort to reduce the incidence and severity of succinylcholine-induced myalgia, various&#xD;
      medications including nondepolarizing muscle relaxants, benzodiazepines, magnesium sulfate,&#xD;
      opioids, gabapentin, and nonsteroidal anti-inflammatory drugs have been tested, with varying&#xD;
      degrees of success.&#xD;
&#xD;
      Duloxetine is an US Food and Drug Administration-approved analgesic used for various pain&#xD;
      syndromes, including diabetic peripheral neuropathy and fibromyalgia. The underlying&#xD;
      mechanism for duloxetine against these pain syndromes remains unclear, but it may involve&#xD;
      three major central nervous system (CNS) targets: (1) serotonin transporter (Ki, 4.6 nM), (2)&#xD;
      norepinephrine transporter (Ki, 16 nM), and (3) dopamine transporter (Ki, 370 nM). In the&#xD;
      past, the antidepressant action was often thought to be the primary mechanism for its&#xD;
      analgesic efficacy. This theory was addressed later by &quot;Path Analysis,&quot; and the result showed&#xD;
      that duloxetine affects pain directly rather than indirectly through mood improvement. In&#xD;
      addition to these multiple CNS targets, duloxetine, like the antidepressant amitriptyline and&#xD;
      the local anesthetic bupivacaine, blocks voltage-gated Na+ channels. Because neuronal Na+&#xD;
      channels are present in both CNS and peripheral nervous systems, such a finding expands the&#xD;
      possible analgesic action and locus of duloxetine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligibility and type of the study: This prospective randomized placebo-controlled&#xD;
      double-blind study will be conducted after approval from the Institutional Ethics Committee&#xD;
      and obtaining written informed consent from patients undergoing elective direct&#xD;
      microlaryngoscopic surgeries under general anesthesia.&#xD;
&#xD;
      Sample size: Sample size calculation is based on the pilot study, where the incidence of POM&#xD;
      in outpatient cases is found to be more than 70% and intervention that can cause 25%&#xD;
      reduction in incidence of POM will be interesting. With a power of 90% and type I error of&#xD;
      5%, 32 patients will be required in each group (α=0.05 and β=90%), but to avoid possible loss&#xD;
      of samples (dropouts) during the study, the number of patients in each group will be&#xD;
      increased to 35 to be a total of 70 patients.&#xD;
&#xD;
      Patients: Seventy patients will be enrolled in this study. They will be equally divided into&#xD;
      two groups. Group D (duloxetine group): 35 patients will receive duloxetine (Cymbalta; Eli&#xD;
      Lilly &amp; Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of&#xD;
      anesthesia. Group C (control group) 35 patients will receive similar-looking placebo capsules&#xD;
      (starch capsules) orally with sips of water, 2 h before induction of anesthesia.&#xD;
&#xD;
      Anesthetic Technique and Data Collection: The patients will not be pre-medicated. The study&#xD;
      drugs will be given to patients by another anesthesiologist blinded to the envelops coding.&#xD;
      No IM injections will be administered during the perioperative period.&#xD;
&#xD;
      Two days before surgery, patients will visit the outpatient clinic for assessment and&#xD;
      explanation about the study protocol. Laboratory investigations will be performed and&#xD;
      patients will be informed that they can stop participation in the study at any time without&#xD;
      any loss of service.&#xD;
&#xD;
      Inside the operating room, standard monitoring (electrocardiogram, non-invasive blood&#xD;
      pressure, heart rate, peripheral oxygen saturation) will be attached and the preliminary&#xD;
      values will be recorded. An intravenous cannula 18G will be inserted in the dorsum of the&#xD;
      non-dominant hand. Anesthesia will be induced with fentanyl 1 mcg/kg, propofol 1.5-2.0 mg/kg&#xD;
      and succinylcholine 1.5 mg/kg.&#xD;
&#xD;
      The intensity of fasciculations will be assessed by an anesthesiologist blinded to the&#xD;
      patient's group allotment based on a four-point scale: (0) Absent, (1) Mild: fine&#xD;
      fasciculations at the eyes, neck, face or fingers without limb movement, (2) Moderate:&#xD;
      fasciculations occurring bilaterally or obvious limb movement and (3) Severe: widespread,&#xD;
      sustained fasciculations. After end of fasciculations, the values of heart rate, non-invasive&#xD;
      blood pressure and oxygen saturation will be measured and recorded.&#xD;
&#xD;
      Patients will be intubated with an appropriate size cuffed endotracheal tube under direct&#xD;
      laryngoscopy after complete muscular relaxation. The endotracheal tube then will be fixed at&#xD;
      the appropriate length, by adhesive tape at the angle of the mouth. After 5 minutes of&#xD;
      tracheal intubation, the previous values will be recorded again. Subsequent values will be&#xD;
      recorded every 5 minutes throughout the surgical procedure. Anesthesia will be maintained&#xD;
      with oxygen 100% and sevoflurane (2-3 MAC). Atracurium bromide 0.5 mg/kg will be given after&#xD;
      endotracheal intubation. The respiratory tidal volume will be adjusted to keep end-tidal CO2&#xD;
      at 35-40 mmHg. All surgical procedures will be completed by the same surgeon.&#xD;
&#xD;
      At the end of the procedure, sevoflurane will be discontinued; residual neuromuscular&#xD;
      blocking agents will be pharmacologically reversed with the standard reversal doses of&#xD;
      neostigmine bromide 0.05 mg/kg in atropine sulphate 0.02 mg/kg. The patients then will be&#xD;
      ventilated by 100% oxygen till full consciousness regains and the patients start following&#xD;
      verbal commands. At that point endotracheal tubes will be removed after gentle suction of&#xD;
      secretions through the tube and the oropharyngeal cavity. After the desired spontaneous&#xD;
      ventilation, the patients will be shifted to post-anesthesia care unit (PACU).&#xD;
&#xD;
      In PACU, Postoperative care will be standardized for all patients. Pain related to surgical&#xD;
      intervention will be treated with paracetamol 1g intravenously (perfalgan; Bristol-Myers&#xD;
      Squibb, New York, USA) given every 8h in both group. The total dose of analgesic requirement&#xD;
      in the first 24 hours will be recorded. After meeting the discharge criteria, the patients&#xD;
      will be discharged to be taken home and cared for, by a responsible adult.&#xD;
&#xD;
      The incidence and severity of myalgia in all patients will be determined 24 hours after&#xD;
      surgery by an anesthesiologist who is unaware of the grouping. Myalgia is defined as &quot;a pain&#xD;
      with no surgical interference&quot; and is graded based on a four-point scale as follows: (0) no&#xD;
      muscle pain, (1) muscle stiffness limited to one area of the body, (2) muscle pain or&#xD;
      stiffness noticed spontaneously by a patient who requires analgesics, and (3) incapacitating&#xD;
      generalized, severe muscle stiffness or pain.&#xD;
&#xD;
      The postoperative sedation level will be assessed by the Ramsay sedation score which consists&#xD;
      of the following six grades: (1) anxious and agitated, (2) cooperative, oriented and&#xD;
      tranquil, (3) responding to commands only, (4) brisk response to light glabellar tap or loud&#xD;
      auditory stimulus, (5) sluggish response to light glabellar tap or loud auditory stimulus,&#xD;
      and (6) no response to light glabellar tap.&#xD;
&#xD;
      Any complications like postoperative nausea, vomiting, dizziness, somnolence, vertigo,&#xD;
      confusion will be recorded and managed accordingly. Nausea will be treated by 10 mg&#xD;
      metoclopramide intravenously, vomiting will be treated by 4 mg ondansetron intravenously.&#xD;
&#xD;
      Patients' Satisfaction: assessment of patients' satisfaction with the overall preoperative&#xD;
      care will be recorded and analyzed.&#xD;
&#xD;
      Statistical analysis:&#xD;
&#xD;
      Data will be performed using a standard SPSS software package version 21 (SPSS Inc., Chicago,&#xD;
      Illinois, USA). Data will be expressed as mean ± SD, numbers (n), and median (range). The&#xD;
      demographic data will be analyzed by Student t-test. Male and female data will be analyzed&#xD;
      with the Chi square test. The consumption of analgesia and sedation in groups will be&#xD;
      analyzed by using Student t-test. The incidence and severity of fasciculation and POM will be&#xD;
      analyzed using Fisher's exact test. Pearson's r correlation will be used to test the&#xD;
      correlation between fasciculations and postoperative myalgia. A p-value of &lt;0.05 will be&#xD;
      considered statistically significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2017</start_date>
  <completion_date type="Actual">November 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 30, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Four-point scale for myalgia</measure>
    <time_frame>24 hours</time_frame>
    <description>Myalgia is defined as &quot;a pain with no surgical interference&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Four-point scale for fasciculations</measure>
    <time_frame>5 minutes</time_frame>
    <description>Score to assess the intensity of fasciculations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramsay sedation score</measure>
    <time_frame>24 hours</time_frame>
    <description>To assess the postoperative sedation level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Complications</measure>
    <time_frame>24 hours</time_frame>
    <description>Percentage of patients with any complications will be recorded and treated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Postoperative Myalgia</condition>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>35 patients will receive duloxetine (Cymbalta; Eli Lilly &amp; Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>35 patients will receive duloxetine (Cymbalta; Eli Lilly &amp; Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.</description>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age 20-60 years&#xD;
&#xD;
          -  either sex&#xD;
&#xD;
          -  ASA physical status I or II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known allergy to duloxetine, abnormal renal and liver function tests, history of&#xD;
             chronic pain&#xD;
&#xD;
          -  regular medication with SNRI or analgesics (excluding acetaminophen and nonsteroidal&#xD;
             anti-inflammatory drugs)&#xD;
&#xD;
          -  patients with a history of seizure disorders&#xD;
&#xD;
          -  hyperkalemia&#xD;
&#xD;
          -  systemic illness like hypertension&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  increased intracranial and intraocular pressure&#xD;
&#xD;
          -  pregnant or breast-feeding females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>OSAMA A. IBRAHIM, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university hospital</name>
      <address>
        <city>Assiut</city>
        <zip>71515</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 26, 2017</study_first_submitted>
  <study_first_submitted_qc>January 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>October 15, 2020</last_update_submitted>
  <last_update_submitted_qc>October 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohamed F. Mostafa</investigator_full_name>
    <investigator_title>Lecturer of Anesthesia and Intensive Care</investigator_title>
  </responsible_party>
  <keyword>Duloxetine</keyword>
  <keyword>Succinylcholine</keyword>
  <keyword>Postoperative Myalgia</keyword>
  <keyword>Microlaryngoscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03037073
org study id: Duloxetine POM
nct id: NCT03037073
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
For >60 years, succinylcholine is still being administered as a selective relaxant for rapid
      sequence intubation by anesthesiologists in many countries. It has been shown to possess
      unique features such as low cost, fast-acting, short half-life, safe metabolites, and causing
      excellent muscle relaxation for intubation. It has many side effects as well. Postoperative
      myalgia (POM), with an incidence rate of ~41%-92%, is one of the most common side effects of
      this drug and can take several days to cause significant discomfort in patients. However, its
      effect is felt more in the throat, neck, shoulder, and abdominal muscles and is common among
      patients with outpatient surgery. Due to its unknown real context of pathogenesis and in an
      effort to reduce the incidence and severity of succinylcholine-induced myalgia, various
      medications including nondepolarizing muscle relaxants, benzodiazepines, magnesium sulfate,
      opioids, gabapentin, and nonsteroidal anti-inflammatory drugs have been tested, with varying
      degrees of success.

      Duloxetine is an US Food and Drug Administration-approved analgesic used for various pain
      syndromes, including diabetic peripheral neuropathy and fibromyalgia. The underlying
      mechanism for duloxetine against these pain syndromes remains unclear, but it may involve
      three major central nervous system (CNS) targets: (1) serotonin transporter (Ki, 4.6 nM), (2)
      norepinephrine transporter (Ki, 16 nM), and (3) dopamine transporter (Ki, 370 nM). In the
      past, the antidepressant action was often thought to be the primary mechanism for its
      analgesic efficacy. This theory was addressed later by "Path Analysis," and the result showed
      that duloxetine affects pain directly rather than indirectly through mood improvement. In
      addition to these multiple CNS targets, duloxetine, like the antidepressant amitriptyline and
      the local anesthetic bupivacaine, blocks voltage-gated Na+ channels. Because neuronal Na+
      channels are present in both CNS and peripheral nervous systems, such a finding expands the
      possible analgesic action and locus of duloxetine.
Eligibility and type of the study: This prospective randomized placebo-controlled
      double-blind study will be conducted after approval from the Institutional Ethics Committee
      and obtaining written informed consent from patients undergoing elective direct
      microlaryngoscopic surgeries under general anesthesia.

      Sample size: Sample size calculation is based on the pilot study, where the incidence of POM
      in outpatient cases is found to be more than 70% and intervention that can cause 25%
      reduction in incidence of POM will be interesting. With a power of 90% and type I error of
      5%, 32 patients will be required in each group (α=0.05 and β=90%), but to avoid possible loss
      of samples (dropouts) during the study, the number of patients in each group will be
      increased to 35 to be a total of 70 patients.

      Patients: Seventy patients will be enrolled in this study. They will be equally divided into
      two groups. Group D (duloxetine group): 35 patients will receive duloxetine (Cymbalta; Eli
      Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of
      anesthesia. Group C (control group) 35 patients will receive similar-looking placebo capsules
      (starch capsules) orally with sips of water, 2 h before induction of anesthesia.

      Anesthetic Technique and Data Collection: The patients will not be pre-medicated. The study
      drugs will be given to patients by another anesthesiologist blinded to the envelops coding.
      No IM injections will be administered during the perioperative period.

      Two days before surgery, patients will visit the outpatient clinic for assessment and
      explanation about the study protocol. Laboratory investigations will be performed and
      patients will be informed that they can stop participation in the study at any time without
      any loss of service.

      Inside the operating room, standard monitoring (electrocardiogram, non-invasive blood
      pressure, heart rate, peripheral oxygen saturation) will be attached and the preliminary
      values will be recorded. An intravenous cannula 18G will be inserted in the dorsum of the
      non-dominant hand. Anesthesia will be induced with fentanyl 1 mcg/kg, propofol 1.5-2.0 mg/kg
      and succinylcholine 1.5 mg/kg.

      The intensity of fasciculations will be assessed by an anesthesiologist blinded to the
      patient's group allotment based on a four-point scale: (0) Absent, (1) Mild: fine
      fasciculations at the eyes, neck, face or fingers without limb movement, (2) Moderate:
      fasciculations occurring bilaterally or obvious limb movement and (3) Severe: widespread,
      sustained fasciculations. After end of fasciculations, the values of heart rate, non-invasive
      blood pressure and oxygen saturation will be measured and recorded.

      Patients will be intubated with an appropriate size cuffed endotracheal tube under direct
      laryngoscopy after complete muscular relaxation. The endotracheal tube then will be fixed at
      the appropriate length, by adhesive tape at the angle of the mouth. After 5 minutes of
      tracheal intubation, the previous values will be recorded again. Subsequent values will be
      recorded every 5 minutes throughout the surgical procedure. Anesthesia will be maintained
      with oxygen 100% and sevoflurane (2-3 MAC). Atracurium bromide 0.5 mg/kg will be given after
      endotracheal intubation. The respiratory tidal volume will be adjusted to keep end-tidal CO2
      at 35-40 mmHg. All surgical procedures will be completed by the same surgeon.

      At the end of the procedure, sevoflurane will be discontinued; residual neuromuscular
      blocking agents will be pharmacologically reversed with the standard reversal doses of
      neostigmine bromide 0.05 mg/kg in atropine sulphate 0.02 mg/kg. The patients then will be
      ventilated by 100% oxygen till full consciousness regains and the patients start following
      verbal commands. At that point endotracheal tubes will be removed after gentle suction of
      secretions through the tube and the oropharyngeal cavity. After the desired spontaneous
      ventilation, the patients will be shifted to post-anesthesia care unit (PACU).

      In PACU, Postoperative care will be standardized for all patients. Pain related to surgical
      intervention will be treated with paracetamol 1g intravenously (perfalgan; Bristol-Myers
      Squibb, New York, USA) given every 8h in both group. The total dose of analgesic requirement
      in the first 24 hours will be recorded. After meeting the discharge criteria, the patients
      will be discharged to be taken home and cared for, by a responsible adult.

      The incidence and severity of myalgia in all patients will be determined 24 hours after
      surgery by an anesthesiologist who is unaware of the grouping. Myalgia is defined as "a pain
      with no surgical interference" and is graded based on a four-point scale as follows: (0) no
      muscle pain, (1) muscle stiffness limited to one area of the body, (2) muscle pain or
      stiffness noticed spontaneously by a patient who requires analgesics, and (3) incapacitating
      generalized, severe muscle stiffness or pain.

      The postoperative sedation level will be assessed by the Ramsay sedation score which consists
      of the following six grades: (1) anxious and agitated, (2) cooperative, oriented and
      tranquil, (3) responding to commands only, (4) brisk response to light glabellar tap or loud
      auditory stimulus, (5) sluggish response to light glabellar tap or loud auditory stimulus,
      and (6) no response to light glabellar tap.

      Any complications like postoperative nausea, vomiting, dizziness, somnolence, vertigo,
      confusion will be recorded and managed accordingly. Nausea will be treated by 10 mg
      metoclopramide intravenously, vomiting will be treated by 4 mg ondansetron intravenously.

      Patients' Satisfaction: assessment of patients' satisfaction with the overall preoperative
      care will be recorded and analyzed.

      Statistical analysis:

      Data will be performed using a standard SPSS software package version 21 (SPSS Inc., Chicago,
      Illinois, USA). Data will be expressed as mean ± SD, numbers (n), and median (range). The
      demographic data will be analyzed by Student t-test. Male and female data will be analyzed
      with the Chi square test. The consumption of analgesia and sedation in groups will be
      analyzed by using Student t-test. The incidence and severity of fasciculation and POM will be
      analyzed using Fisher's exact test. Pearson's r correlation will be used to test the
      correlation between fasciculations and postoperative myalgia. A p-value of <0.05 will be
      considered statistically significant.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: Double (Participant, Investigator)
measure: Four-point scale for myalgia
time frame: 24 hours
description: Myalgia is defined as "a pain with no surgical interference"
measure: Four-point scale for fasciculations
time frame: 5 minutes
description: Score to assess the intensity of fasciculations
measure: Ramsay sedation score
time frame: 24 hours
description: To assess the postoperative sedation level
measure: Postoperative Complications
time frame: 24 hours
description: Percentage of patients with any complications will be recorded and treated
arm group label: Group D
arm group type: Active Comparator
description: 35 patients will receive duloxetine (Cymbalta; Eli Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
arm group label: Group C
arm group type: Active Comparator
description: 35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
intervention type: Drug
intervention name: Duloxetine
description: 35 patients will receive duloxetine (Cymbalta; Eli Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
arm group label: Group D
intervention type: Drug
intervention name: Placebo oral capsule
description: 35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
arm group label: Group C
criteria: 
gender: All
minimum age: 20 Years
maximum age: 60 Years
healthy volunteers: No
last name: OSAMA A. IBRAHIM, MD
role: Study Chair
affiliation: Assiut University
facility: 
country: Egypt
responsible party type: Principal Investigator
investigator affiliation: Assiut University
investigator full name: Mohamed F. Mostafa
investigator title: Lecturer of Anesthesia and Intensive Care
mesh term: Myalgia
mesh term: Duloxetine Hydrochloride
sharing ipd: Undecided